Abstract
Aim: To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs). Patients & methods: Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment. Results: At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1 vs 98.7; QoL 94.2 vs 99.1; p < 0.001). A statistically significant reduction in antibiotic use was reported. Conclusion: This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.
להמשך קריאה
Tommaso Cai, Irene Tamanini, Andrea Cocci, Fabrizio di Maida, Patrizio Caciagli, Serena Migno, Liliana Mereu, Saverio Tateo, Gianni Malossini, Alessandro Palmieri, Paolo Verze, Vincenzo Mirone, and Truls E Bjerklund Johansen
Future Microbiology 2019 14:12, 1013-1021
'מערכת אימד'
